MedElevator Войти в исследования
← Поиск публикаций

DOI 10.19746/j.cnki.issn.1009-2137.2025.03.014

Медицинская библиотека · Zhongguo shi yan xue ye xue za zhi · 2025

[Curative Efficacy Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia with ASXL1 Mutation].

Shi Ya-Jie, Xie Xin-Sheng, Jiang Zhong-Xing, Wan Ding-Ming, Guo Rong, Li Tao, Zhang Xia, Li Xue, Zhang Yu-Pei, Su Yue

Аннотация на английскомСтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

To explore the efficacy and apoptosis of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of acute myeloid leukemia (AML) with ASXL1 mutation.

METHODS

The clinical data of 80 AML patients with ASXL1 mutation treated in our hospital from January 2019 to December 2021 were retrospectively analyzed. The clinical characteristics of the patients were summarized, and the therapeutic effect and prognostic factors of allo-HSCT for the patients were analyzed.

RESULTS

Among the 80 patients, 38 were males and 42 were females, and the median age was 39(14-65) years. There were 17 patients in low-risk group, 25 patients in medium-risk group and 38 patients in high-risk group. ASXL1 mutation co-occurred with many other gene mutations, and the frequent mutated genes were TET2 (71.25%), NRAS (18.75%), DNMT3A (16.25%), NPM1 (15.00%), CEBPA (13.75%). Among medium and high-risk patients, 29 underwent allo-HSCT, while 34 received chemotherapy. The 2-year overall survival (OS) rate and disease-free survival (DFS) rate of the allo-HSCT group were 72.4% and 70.2%, while those of the chemotherapy group were 44.1% and 34.0%, respectively. The statistical analysis showed significant differences between the two groups (both P < 0.01). Multivariate analysis showed that age at transplantation >50- years and occurrence of acute graft-versus-host disease after transplantation were poor prognostic factors for OS and DFS in transplantation patients.

CONCLUSION

Allo-HSCT can improve the prognosis of AML patients with ASXL1 mutation.

Для цитирования: Shi Ya-Jie, Xie Xin-Sheng, Jiang Zhong-Xing, Wan Ding-Ming, Guo Rong, Li Tao, Zhang Xia, Li Xue, Zhang Yu-Pei, Su Yue. [Curative Efficacy Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia with ASXL1 Mutation].. Zhongguo shi yan xue ye xue za zhi. 2025. DOI: 10.19746/j.cnki.issn.1009-2137.2025.03.014.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.